Eli Lilly and Company: Melanoma trials
The registry lists 14 Melanoma studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 9Phase 2 3Phase 3 1No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced CancerCompletedNCT04148937Phase 1Results posted
- A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the BrainCompletedNCT02308020Phase 2Results posted
- A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their BodyTerminatedNCT02014116Phase 1Results posted
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid TumorsCompletedNCT02009449Phase 1Results posted
- An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant MelanomaCompletedNCT01137006Phase 1Results posted
- A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic MelanomaTerminatedNCT01006252Phase 3Results posted
- A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant MelanomaCompletedNCT00533702Phase 2Results posted
- A Study of Tasisulam in Treating Participants With Malignant MelanomaCompletedNCT00383292Phase 2Results posted
- FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)TerminatedNCT05432193Phase 1
- Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingNCT04521686Phase 1
- An Expanded Access Program for AM0010 (Pegilodecakin)No longer availableNCT03554434
- A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerCompletedNCT02857270Phase 1
- A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsCompletedNCT02791334Phase 1
- Study of gp75 Vaccine in Patients With Stage III and IV MelanomaCompletedNCT00034554Phase 1